Carol Ann

Enrich Biosystems Joins Cell Manufacturing Research Initiative to Further Advance Cell Therapy Discovery

Retrieved on: 
Monday, August 14, 2023
Emory University, Morgridge Institute for Research, Georgia Tech, Fraunhofer Competence Field Additive Manufacturing, University, University of Puerto Rico at Humacao, NSF, Wallace H. Coulter Department of Biomedical Engineering, National Science Foundation, Cancer, DSM-IV codes, Research, Carol Ann, Biomedical engineering, University of Wisconsin–Madison, Common, Biomedicine, Patient, Cell, Conditional sentence, BioSystems, University of Oregon, Wallace, Kinetics, Pharmaceutical industry

BRANFORD, Conn., Aug. 14, 2023 /PRNewswire-PRWeb/ -- Enrich Biosystems, a pioneering early-stage biotech company developing a unique microfluidics-free cell analysis and isolation technology, today announced it has joined the National Science Foundation (NSF) Engineering Research Center for Cell Manufacturing Technologies (CMaT). CMaT is a consortium of universities, companies, and clinical collaborators brought together to develop transformative tools and technologies for the consistent, scalable, and low-cost production of high-quality living therapeutic cells. Launched in 2017 with investment from NSF, the Center aims to revolutionize the treatment of cancer, heart disease, neurological disorders, and other chronic diseases by enabling the broad use of potentially curative therapies utilizing living cells.

Key Points: 
  • Enrich Biosystems has revolutionized cancer cell therapy discovery with its cutting-edge microfluidics-free technology.
  • Enrich technology simplifies the process of cell co-culturing and kinetics profiling to conduct guided capturing based on cell behaviors and functions.
  • "By partnering with the Enrich team, we aim to improve the current processes of discovery and manufacturing for critical cell therapies.
  • "The Enrich team is thrilled and proud to join the CMaT community," said Dong Wang, CEO at Enrich Biosystems.